Cytokinetics (NASDAQ:CYTK) Announces Earnings Results

by · The Markets Daily

Cytokinetics (NASDAQ:CYTK – Get Free Report) announced its earnings results on Wednesday. The biopharmaceutical company reported ($1.37) earnings per share for the quarter, topping the consensus estimate of ($1.44) by $0.07, Zacks reports. The company had revenue of $47.56 million for the quarter, compared to analysts’ expectations of $41.88 million. The company’s quarterly revenue was up 2356.5% compared to the same quarter last year. During the same period last year, the business earned ($2.55) EPS.

Here are the key takeaways from Cytokinetics’ conference call:

  • MYQORZO generated $44.5 million in Q3 net product revenue, up 76% sequentially. Prescribers and dispensed patients grew, while new-to-brand share approached 45%; the company is targeting more than 50% by year-end.
  • Cytokinetics plans to submit an aficamten supplemental NDA for symptomatic non-obstructive HCM this quarter, following positive Phase 3 ACACIA-HCM results. The company is also preparing for a potential 2027 launch, though approval and the eventual label remain uncertain.
  • MYQORZO’s international rollout is progressing, with Germany showing early traction and a U.K. launch expected this quarter. The company expects launches in additional countries in 2027, while noting broader European revenue may take until 2028–2029 to build meaningfully.
  • The company ended Q3 with approximately $1.6 billion in cash and investments and reaffirmed 2026 combined R&D and SG&A expense guidance of $860 million–$890 million. Quarterly SG&A increased to $113.1 million as commercial launch costs rose, while the company reported a $190.1 million net loss.

Cytokinetics Price Performance

Shares of CYTK stock traded up $1.29 during trading hours on Wednesday, reaching $63.60. 2,916,652 shares of the stock were exchanged, compared to its average volume of 1,525,180. Cytokinetics has a 12-month low of $58.05 and a 12-month high of $88.31. The business’s fifty day moving average is $66.63 and its two-hundred day moving average is $70.05. The firm has a market capitalization of $7.91 billion, a P/E ratio of -8.81 and a beta of 0.45.

Analysts Set New Price Targets

CYTK has been the subject of a number of recent analyst reports. Morgan Stanley upgraded shares of Cytokinetics from an “overweight” rating to a “buy” rating in a research report on Tuesday, September 1st. JPMorgan Chase & Co. upped their price objective on shares of Cytokinetics from $97.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. Truist Financial increased their price objective on shares of Cytokinetics from $106.00 to $112.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Needham & Company LLC increased their price objective on shares of Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, Wall Street Zen downgraded shares of Cytokinetics from a “hold” rating to a “sell” rating in a report on Tuesday, October 20th. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cytokinetics currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.44.

Check Out Our Latest Report on CYTK

Insider Activity

In other Cytokinetics news, EVP Andrew Callos sold 10,000 shares of the stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $70.24, for a total value of $702,400.00. Following the sale, the executive vice president directly owned 58,555 shares of the company’s stock, valued at approximately $4,112,903.20. This represents a 14.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Fady Malik sold 3,500 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $68.29, for a total transaction of $239,015.00. Following the completion of the sale, the executive vice president directly owned 153,902 shares in the company, valued at approximately $10,509,967.58. This represents a 2.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 180,926 shares of company stock worth $12,510,340. Insiders own 2.60% of the company’s stock.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

  • Positive Sentiment: Cytokinetics reported a third-quarter loss of $1.37 per share, better than analysts’ expected loss of $1.44, and revenue of $47.56 million versus estimates of $41.88 million. Revenue rose 2,356.5% year over year, and the per-share loss narrowed from $2.55 in the year-ago quarter. Earnings report
  • Neutral Sentiment: CEO Robert Blum and EVP Fady Malik sold shares under pre-arranged Rule 10b5-1 trading plans. The sales totaled 7,500 and 3,500 shares, respectively; both executives retained substantial holdings, which may reduce the significance of the transactions. Insider sale report

About Cytokinetics

(Get Free Report)

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.

See Also